Cite
HARVARD Citation
Roddie, C. et al. (2021). Durable Responses and Low Toxicity After Fast Off-Rate CD19 Chimeric Antigen Receptor-T Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia. Journal of clinical oncology. 39 (30), pp. 3352-3363. [Online].